Biovica International AB

Stocks
, , ,
1

Biovica is a Swedish biotechnology company founded in 2009. It was listed on the stock exchange in 2017. Its main product is the DiviTum TKa test: https://divitum.com/, which is a biomarker test that monitors and predicts treatment response in breast cancer. They received FDA approval in 2022.

The small company has faced challenges in launching the product in the US market, and the start of sales has taken longer than expected. They are now aiming to commercialize the DiviTum TKa test with Tempus AI.

In the last fiscal year, revenue was approximately 8 million SEK. The goal is to increase sales to 50 million Swedish kronor in fiscal year 2025/2026, mainly from US sales. More information on targets: Biovica announces financial targets following key partnerships and commercial progress - Biovica International AB

They just raised 122 million SEK from a share issue for growth. The company’s market capitalization is 195 million SEK.

Redeye report from June before the share issue

https://www.redeye.se/api/articles/download-file/3584aa8d-b126-374e-90eb-e24a8a216c76/Biovica%3A%20Adding%20cash%20and%20increased%20market%20distribution

5 Likes
2

Biovica Q1 Interim report May 2025 – July 2025 - Biovica International AB

11.9 julkaistu osavuosi

Tappio pieneni pikkaisen, mutta ei vielä merkittävää parannusta. Lisää myyntiä vaaditaan, että paastään luvattuun 2026 loppuvuoden voitolliseen tulokseen. Mielenkiinnolla seurailen mitä tapahtuu.

SEK 000s Q1 25/26 Q1 24/25 May-April 24/25
Net sales 2,596 1,714 8,619
Operating profit (loss) -19,334 -23,562 -85,839
Earnings per share, after dilution -0.18 -0.27 -0.95
Number of shares at the end of the period 97,786,384 84,055,560 92,569,248
Cash and cash equivalents at the end of the period 16,305 65,209 24,415
Cash flow from operating activities -17,196 -29,044 -85,367
Average number of employees 25 27 26

Significant events during the first quarter

  • Biovica is now collaborating with Tempus to expand the commercial reach of DiviTum TKa

  • Biovica signed a significant Master Service Agreement (MSA) and first work order under that agreement for SEK 4 million

  • New data on DiviTum TKa for use in three areas of cancer presented at ASCO

  • Biovica secured three new assignments worth SEK 2.5 million in the Pharma Services part of the business

  • Biovica announced financial targets reflecting its important partnership and commercial success

  • Biovica resolved on a fully guaranteed rights issue of approximately SEK 80 million at SEK 0.63 per share

  • Biovica signed an agreement with its fifth Tier 1 biopharma company in the USA

Significant events after the end of the period